Table 1 Pharmacokinetic Parameters in Hypertensive Adults and Children Age 6-16 Following Multiple Dosing   Adults given 50 mg once daily for 7 days
N=12 Age 6-16 given 0.7 mg/kg once daily for 7 days
N=25
* Mean ± standard deviation
† Harmonic mean and standard deviation
‡ Median 
 Parent Active Metabolite Parent Active Metabolite
AUC0-24*(ng•h/mL) 442 ± 173 1685 ± 452 368 ± 169 1866 ± 1076
CMAX (ng/mL)* 224 ± 82 212 ± 73 141 ± 88 222 ± 127
T1/2 (h)† 2.1 ± 0.70 7.4 ± 2.4 2.3 ± 0.8 5.6 ± 1.2
TPEAK (h)‡ 0.9 3.5 2.0 4.1
CLREN (mL/min)* 56 ± 23 20 ± 3 53 ± 33 17 ± 8

The bioavailability of the suspension formulation was compared with losartan tablets in healthy adults. The suspension and tablet are similar in their bioavailability with respect to both losartan and the active metabolite (see DOSAGE AND ADMINISTRATION, Preparation of Suspension).

Geriatric and Gender: Losartan pharmacokinetics have been investigated in the elderly (65-75 years) and in both genders. Plasma concentrations of losartan and its active metabolite are similar in elderly and young hypertensives. Plasma concentrations of losartan were about twice as high in female hypertensives as male hypertensives, but concentrations of the active metabolite were similar in males and females. No dosage adjustment is necessary (see DOSAGE AND ADMINISTRATION).

Race: Pharmacokinetic differences due to race have not been studied (see also PRECAUTIONS, Race and  CLINICAL PHARMACOLOGY, Pharmacodynamics and Clinical Effects, Reduction in the Risk of Stroke, Race).

Renal Insufficiency: Following oral administration, plasma concentrations and AUCs of losartan and its active metabolite are increased by 50-90% in patients with mild (creatinine clearance of 50 to 74 mL/min) or moderate (creatinine clearance 30 to 49 mL/min) renal insufficiency. In this study, renal clearance was reduced by 55-85% for both losartan and its active metabolite in patients with mild or moderate renal insufficiency. Neither losartan nor its active metabolite can be removed by hemodialysis. No dosage adjustment is necessary for patients with renal impairment unless they are volume-depleted (see WARNINGS, Hypotension — Volume-Depleted Patients and DOSAGE AND ADMINISTRATION).

Hepatic Insufficiency: Following oral administration in patients with mild to moderate alcoholic cirrhosis of the liver, plasma concentrations of losartan and its active metabolite were, respectively, 5-times and about 1.7-times those in young male volunteers. Compared to normal subjects the total plasma clearance of losartan in patients with hepatic insufficiency was about 50% lower and the oral bioavailability was about 2-times higher. A lower starting dose is recommended for patients with a history of hepatic impairment (see DOSAGE AND ADMINISTRATION).

Drug Interactions
Losartan, administered for 12 days, did not affect the pharmacokinetics or pharmacodynamics of a single dose of warfarin. Losartan did not affect the pharmacokinetics